Plain-English translation of NCT04913649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After heart surgery, many older patients develop anemia—a condition where the blood doesn't carry enough oxygen because iron levels drop. This trial tests whether a single infusion of ferric derisomaltose (a form of iron given directly into the vein) helps older adults recover better and feel stronger three months after surgery, compared to a placebo infusion. Researchers will track how well participants regain their ability to do daily activities and how they feel overall.
When the heart-lung machine is used during surgery, it can cause blood loss and iron deficiency, which slows recovery and may lead to needing blood transfusions. This medication could help the body rebuild its own blood faster and naturally, potentially improving how well patients bounce back after surgery.
You likely qualify if…
You likely don't qualify if…
On the first day after your heart surgery, you will receive either the iron medication or a placebo—a salt water solution that looks identical—as a single infusion over about one hour. Your vital signs will be monitored during the infusion and for 30 minutes afterward. You will then complete follow-up assessments at 90 days after surgery, answering questions about your ability to perform daily activities, your energy level, and your overall quality of life, and having blood tests to check your blood counts.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
Netherlands